BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Therapeutic Court Association of Washington and Washington Association of Drug Courts - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Therapeutic Court Association of Washington and Washington Association of Drug Courts
X-ORIGINAL-URL:https://tcaofwa.org
X-WR-CALDESC:Events for Therapeutic Court Association of Washington and Washington Association of Drug Courts
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260403T090000
DTEND;TZID=America/Los_Angeles:20260403T100000
DTSTAMP:20260510T225631
CREATED:20260327T004538Z
LAST-MODIFIED:20260327T004538Z
UID:9260-1775206800-1775210400@tcaofwa.org
SUMMARY:Evidence-Based Treatment for Stimulant Use Disorders Among Populations at Elevated Risk for HIV
DESCRIPTION:Brought to you by Opioid Research Network \nEvidence-Based Treatment for Stimulant Use Disorders Among Populations at Elevated Risk for HIV \nFriday April 3\, 2026 12:00 – 1:00 PM ET \nORN Partner Organization Sponsor: National Alliance for HIV Education and Workforce Development (NAHEWD) \nThis lecture will review safety optimization strategies and evidence-based treatments for stimulant use disorders\, including special attention to populations at elevated risk of HIV. The session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series is highlighting various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. \nThis session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series will highlight various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. This lecture will review safety optimization strategies and evidence-based treatments for stimulant use disorders\, including special attention to populations at elevated risk of HIV. By the end of the presentation\, participants will be able to: 1. Contextualize stimulant use disorder and substance use among populations at elevated risk for HIV using epidemiology and syndemic theory. 2. Apply safety optimization techniques to support the wellness of people who use stimulants. 3. Translate clinical research on treatments for stimulants into therapeutic prescribing practices. \nRegister Here: Webinar Registration – Zoom
URL:https://tcaofwa.org/event/evidence-based-treatment-for-stimulant-use-disorders-among-populations-at-elevated-risk-for-hiv/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-174430.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260413T110000
DTEND;TZID=America/Los_Angeles:20260413T120000
DTSTAMP:20260510T225631
CREATED:20260327T005846Z
LAST-MODIFIED:20260327T005846Z
UID:9270-1776078000-1776081600@tcaofwa.org
SUMMARY:Medetomidine Impacts on Clinical Management and Systems of Care
DESCRIPTION:ORN Partner Organization Sponsor: American Osteopathic Academy of Addiction Medicine (AOAAM) \nWednesday May 13\, 2026 5:00 – 6:00 PM ET \nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nDescription:\n\nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation entitled will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nLearning objectives:\nAt the conclusion of this seminar\, attendees should be able to: \n\nDescribe the emergence of medetomidine as an illicit drug adulterant and its impact on overdose toxicity and withdrawal presentations.\nRecognize the clinical features of medetomidine toxicity and differentiate medetomidine withdrawal from withdrawal syndromes.\nApply evidence-informed strategies for early\, aggressive management of medetomidine withdrawal\, including the use of alpha-2 agonists and antiemetic therapies.\nIdentify system-level challenges posed by medetomidine and outline approaches to multidisciplinary coordination.\n\nWhat is ORN\n\n\nHelp is here! The Opioid Response Network (ORN) is your resource for no-cost education\, training and consultation to enhance efforts addressing opioid and stimulant use disorders.\nORN has consultants in every state and territory to deploy across prevention\, treatment\, recovery and harm reduction.\nShare your needs via the “Submit a Request” form at www.OpioidResponseNetwork.org. Within one business day\, your regional point person will be in touch to learn more.\n\nSpeaker: \nMichael Lynch\, MD \n\nDr. Michael Lynch is an associate professor of Emergency Medicine\, Toxicology\, and Addiction Medicine at the University of Pittsburgh where he works clinically in several UPMC hospitals. He is currently Senior Medical Director for Quality and Substance Use Disorder Services at UPMC Health Plan. He previously served as the first Medical Director of the PA Department of Drug and Alcohol Programs and was Medical Director of the Pittsburgh Poison Center for 10 years. Dr. Lynch is the founder and director of the UPMC Medical Toxicology Telemedicine Bridge Clinic. \nDISCLAIMER\nACCREDITATION:\nIn support of improving patient care\, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nDISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:\nAll conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships\, or the lack thereof\, will be provided to learners.\n\nFunding:\nFunding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names\, commercial practices\, or organizations imply endorsement by the U.S. Government.\n\n\n\nRegister Here: ORN Spring 2026: Medetomidine Impacts on Clinical Management and Systems of Care\n\n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/medetomidine-impacts-on-clinical-management-and-systems-of-care/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-175327.png
END:VEVENT
END:VCALENDAR